Retatrutide and Hair Loss

Two statements, and the whole page is the evidence for them.

Hair loss is not reported as an adverse event in any retatrutide trial readout. Not in the four TRIUMPH Phase 3 releases, not in the 2023 Phase 2 publication in the New England Journal of Medicine.

Shedding after rapid weight loss is a well-characterised dermatological phenomenon with its own name, its own mechanism and its own timeline. It is called telogen effluvium, it follows large and fast weight reductions of any cause, and the published reviews of this drug class attribute the hair loss reported around these compounds to it rather than to direct toxicity to the follicle.

The retatrutide adverse event record is narrow and specific. What Lilly reported across the Phase 3 programme is a gastrointestinal cluster and one neurological event. Nausea ran 28.6% to 42.4% across the TRIUMPH-1 dose arms, diarrhoea 25.2% to 34.1%, constipation 23.8% to 26.1%. Dysesthesia, an altered skin sensation, appears in all four Phase 3 readouts and reached 20.9% at 12mg in TRIUMPH-4. Full frequencies by trial and arm are in the side effects filing.

Alopecia, hair thinning and hair shedding do not appear in that record at all.

One qualification is owed, because it is the difference between reporting and overclaiming. These are topline sponsor releases, and topline releases list the events that crossed a frequency threshold. They are not full adverse event tables. An event occurring below the reporting threshold would not appear, and the peer-reviewed publication of the TRIUMPH datasets and any FDA review documents following the planned Q1 2027 filing are where a complete table would become visible. What can be said now is that hair loss did not reach the level at which any of the four readouts thought it worth reporting, in a programme covering roughly 5,900 participants.

Hair follicles cycle rather than grow continuously. Each one runs through anagen, the growth phase, which lasts years, then a brief transitional catagen, then telogen, a resting phase of roughly three months at the end of which the hair is released and a new anagen hair begins. At any moment a normal scalp has most of its follicles in anagen and a small minority in telogen.

Telogen effluvium is what happens when a systemic stressor pushes an abnormally large share of follicles into telogen simultaneously. The shedding is diffuse across the whole scalp rather than patterned, it does not scar, and the follicle itself is not destroyed. It is a synchronisation event, not a destruction event, which is why the usual course is self-limiting.

The recognised triggers are a list of physiological shocks: major surgery, high fever and severe illness, childbirth, certain medications, psychological stress, and crash dieting, severe caloric restriction and rapid weight loss. That last group is why this page exists. A person losing a quarter of their body weight over eighteen months has, from the follicle's point of view, been through a sustained physiological stressor with an energy deficit attached to it.

The single most useful fact about telogen effluvium is its delay. The shedding does not begin when the trigger begins. It begins two to three months later, because the follicles pushed into telogen have to sit through the resting phase before they release their hairs.

That delay is why the phenomenon gets misattributed constantly. Someone who began a rapid weight reduction in January and notices shedding in April will connect it to whatever changed in April. The dermatology answer is that the relevant event was in January.

It also means the shedding often arrives at the point where the weight loss curve is steepest. In the retatrutide record the sharpest phase of reduction is early, as set out in the results timeline filing, and the escalation ladder in the titration filing reaches maintenance dose between week 4 and week 16 depending on the arm. Two to three months after that is the window the literature describes.

The clearest dataset is a single-centre retrospective study published in Annals of Dermatology in December 2024. It examined 140 patients presenting with telogen effluvium attributed to weight loss, 30 men and 110 women, mean age 34.6 years, from records spanning 2006 to 2021.

Two numbers from it are worth carrying. Mean weight loss in that group was 15.21% of body weight, with a standard deviation of 7.18%. Mean rate of loss was 3.54kg per month, with a standard deviation of 2.85. Men in the series had lost weight faster than women, at 5.03kg per month against 3.14. The proportion of body weight lost was highest in teenagers and declined with age, and the authors concluded that women and older adults were particularly vulnerable even when the degree of loss was not more severe.

Nothing in that cohort involves an incretin drug. These were people losing weight, and losing hair for it.

The bariatric surgery literature says the same thing in a different population. A 2021 Cureus case report and review, published under the label bariatric surgery-induced telogen effluvium, describes alopecia after weight loss surgery as acute in onset within the first three months and associated with telogen effluvium, with later onset around six months more often connected to nutritional deficiency. Again, no drug involved. Rapid weight loss on its own is sufficient.

There is a real body of evidence around GLP-1 receptor agonists and hair, and it would be dishonest to leave it out because retatrutide is absent from it.

A 2026 systematic review in Science Progress collated the trial figures. Among them: alopecia in 7% of tirzepatide participants against 1.4% on placebo in one SURMOUNT report, 5.1%, 4.9% and 5.7% across the tirzepatide 5mg, 10mg and 15mg arms against 0.9% on placebo in another, and 7% against 3% in a high dose oral semaglutide trial at 50mg. Pooled, the review described an alopecia incidence of 6.0 per 1,000 patient-years on GLP-1 receptor agonists against 0.8 per 1,000 patient-years on placebo, roughly a threefold difference.

A large real-world cohort study drawn from the TriNetX US network, matching 547,993 GLP-1 receptor agonist users against the same number of controls, reported adjusted odds ratios at twelve months of 1.76 for telogen effluvium, 1.64 for androgenetic alopecia and 1.40 for non-scarring hair loss overall. Alopecia areata was not significant.

If the mechanism is weight loss rather than the molecule, the variables that matter are the ones that describe the weight loss. Two dominate the published discussion.

The rate. The Annals of Dermatology series characterised its cohort by rate as well as magnitude, at 3.54kg per month, and found the faster-losing subgroup was the male one. Rate of loss is the variable the dermatology literature keeps returning to, and it is the one that distinguishes a gradual reduction from a physiological shock.

Nutritional adequacy, protein above all. The bariatric literature treats post-operative hair loss substantially as a nutrition question, with protein, iron and zinc the recurring subjects. Severe caloric restriction reduces intake of everything at once, and hair follicles are among the most metabolically demanding structures in the body. This is also the point of contact with the lean mass filing, because protein intake during weight reduction is discussed in both literatures for related reasons.

Both of those are reported here as what the research discusses. Neither has been studied in a retatrutide trial. No trial in this programme randomised participants to different protein intakes or different rates of loss, and nothing in this section is a recommendation to anyone about diet or dosing.

Here is the honest position, stated as directly as it can be.

Retatrutide-specific evidence on hair: none. No reported adverse event in four Phase 3 readouts covering roughly 5,900 participants, and none in Phase 2.

Class-level evidence: present, and it points at the weight loss. Trial-level alopecia rates exist for tirzepatide and high dose oral semaglutide, a large cohort study finds elevated odds, and the systematic review that assembled all of it concluded the mechanism is telogen effluvium secondary to rapid loss and caloric restriction.

The extrapolation, and its limit. Retatrutide produces the largest weight reductions in this class: 28.3% at 80 weeks in TRIUMPH-1 and 30.3% in the 104-week extension, against 22.5% for tirzepatide in SURMOUNT-1 at 72 weeks and 14.9% for semaglutide in STEP 1 at 68 weeks. If the driver is the magnitude and rate of weight loss, then a compound producing more of it sits at the same end of that relationship. That is a reasonable inference. It is not a finding, no trial has tested it, and it should be labelled as inference every time it is repeated.

What would change this page is the peer-reviewed publication of the full TRIUMPH adverse event tables, or FDA review documents following the planned Q1 2027 filing. Until then, the record is what it is.

Retatrutide is not approved in any market and is not registered with FDA Philippines, so in this country it exists as research material rather than as a medicine. Lilly stated in July 2026 that it plans to submit a Biologics License Application to the US FDA in Q1 2027. The country picture is in the retatrutide Philippines filing, the regulatory background in the FDA Philippines guide, and the wider class comparison in the GLP-1 side effects overview.

One practical note for readers in a tropical climate. Diffuse shedding has many causes, several of them common and unrelated to weight, including thyroid disorders, iron deficiency, febrile illness and postpartum change. Persistent, patterned or scarring hair loss is a dermatological question and not a peptide question, and it belongs with a clinician rather than with a search result.

1. [01]Clinical seriesAnn Dermatol 2024 · Telogen effluvium associated with weight loss

   Single-centre retrospective study, 140 patients, 30 men and 110 women, mean age 34.57 years. Mean weight loss 15.21% at 3.54kg per month. Ann Dermatol 2024;36(6):384-388.

   pubmed.ncbi.nlm.nih.gov/39623615
2. [02]ReviewCureus 2021 · Bariatric surgery-induced telogen effluvium

   Case report and review of hair loss following weight loss surgery. Source for the acute onset within three months pattern and the later, nutrition-associated presentation. Cureus 2021;13(4):e14617.

   pubmed.ncbi.nlm.nih.gov/34055500
3. [03]Systematic reviewScience Progress 2026 · GLP-1 therapies and hair loss

   Gupta AK et al. Systematic review of current evidence and implications for counseling. Source for the trial-level alopecia rates in tirzepatide and oral semaglutide, the 6.0 against 0.8 per 1,000 patient-years figure, and the conclusion that rapid weight loss rather than direct drug toxicity is the likely driver.

   pmc.ncbi.nlm.nih.gov/articles/PMC13100445
4. [04]Cohort studyTriNetX multicentre cohort · Hair loss with GLP-1 receptor agonists

   Matched cohorts of 547,993 each, TriNetX US Collaborative Network. Adjusted odds ratios at twelve months: telogen effluvium 1.76 (95% CI 1.34 to 2.32), androgenetic alopecia 1.64 (1.35 to 1.99), non-scarring hair loss overall 1.40 (1.31 to 1.49).

   pmc.ncbi.nlm.nih.gov/articles/PMC12997224
5. [05]TrialLilly · TRIUMPH-1 readout, 21 May 2026

   The pivotal obesity trial, n=2,339 over 80 weeks. Source for the reported adverse event profile, which is gastrointestinal plus dysesthesia and does not include alopecia.

   investor.lilly.com · TRIUMPH-1 release